Unified classification and risk-stratification in Acute Myeloid Leukemia

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Current Acute Myeloid Leukemia (AML) classification and risk stratification rely heavily on cytogenetic findings, which are only available in less than 50% of patients.
• This limits accurate prognostication and treatment planning for a significant portion of AML cases.

Purpose of the Study:

• To develop a comprehensive molecular classification system for Acute Myeloid Leukemia (AML) that captures all patients.
• To associate these molecular classes with distinct clinical characteristics, treatment responses, and prognostic outcomes.
• To create a refined risk-stratification score and a clinical decision support tool for AML.

Main Methods:

• Utilized comprehensive molecular profiling data from 3,653 Acute Myeloid Leukemia (AML) patients.
• Characterized and validated 16 distinct molecular classes encompassing 100% of AML cases.
• Developed a 3-tier risk-stratification score based on molecular class membership and integrated cytogenetic and gene data.

Main Results:

• Identified 16 molecular classes that describe all Acute Myeloid Leukemia (AML) patients, each linked to specific clinical presentations and outcomes.
• The Secondary AML-2 class (24%) showed high-risk disease and poor prognosis, benefiting significantly from transplantation.
• The novel risk-stratification score re-stratified 26% of patients compared to standard methods, and an open-access decision support tool was created.

Conclusions:

• A unified framework for Acute Myeloid Leukemia (AML) classification and risk-stratification using molecular profiling and gene data has been established.
• This molecular classification improves upon traditional methods, offering more accurate prognostication and personalized treatment guidance.
• The developed tools aim to enhance clinical decision-making and patient outcomes in AML management.